Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry

• Conditions: Acute Coronary Syndrome; Dyslipidemias
• Interventions: Drug: Statin

• Registration Number: NCT05081336
• Lead Sponsor: University Clinical Centre of Republic of Srpska

Brief Summary

Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS). However, the data coming from the real-world setting are limited. Therefore, the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS.

Patients with ACS will be followed for mortality and major events for at least 1 year. Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-01
• Status Verified: 2021-10
• Study First Submitted: 2021-10-05
• Study First Submitted QC: 2021-10-05
• Last Update Submitted: 2021-10-17
• Study First Posted: 2021-10-18
• Last Update Posted: 2021-10-25
• Primary Completion: 2023-01
• Study Completion: 2023-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• acute coronary syndrome

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
High-intensity statin	Statin	-
High-intensity statin plus ezetimib	Statin	-
High-intensity statin plus ezetimib plus PCSK9 inhibitor	Statin	-

Primary Outcome Measures

Name	Time	Method
Major Cardiovascular Adverse Events	1 year	All-cause death, Acute Coronary Syndrom, Need for Myocardial Revascularization

Secondary Outcome Measures

Name	Time	Method
LDL reduction	1 year

Trial Locations

Locations (1)

University Clinical Centre of the Republic of Srpska; 🇧🇦 Banja Luka, Republic Of Srpska, Bosnia and Herzegovina